Antibody Bank
(Kato's Lab; Tohoku University)
Kato' lab in Tohoku University Graduate School of Medicine
mAb list
ACKR1/ ATRX/ CA4/ CCR1/ CCR2/ CCR3/ CCR4/ CCR5/ CCR6/ CCR8/ CCR9/ CCR11/ CD10/ CD19/ CD20/ CD39/ CD44s/ CD44v3/ CD44v4/ CD44v5/ CD44v6/ CD44v7/ CD44v8/ CD44v9/ CD44v10/ CD133/ CD271/ CD273/ CD274/ CD276/ CDH1/ CXCR1/ CXCR2/ CXCR3/ CXCR4/ CXCR5/ CXCR6/ CXCR7/ DGK/ EGFR/ EpCAM/ EphA1/ EphA6/ EphA8/ EphB1/ EphB2/ EphB4/ EphB6/ GPC1/ GPC3/ HER2/ HER3/ HER4/ HGF/ IDH/ KLRG1/ PD-L1/ PD-L2/ PODXL/ PDPN (mouse; rat; rabbit; dog; bovine; cat; tiger; horse; pig; goat; alpaca; Tas_devil; bear; whale; sheep; sea_lion; elephant; ferret; hamster; giraffe; panda)/ RdRP/ SARS-CoV-2 (N/ S2/ bispecific)/ TERT/ TIGIT/ TROP2/XCR1
anti-Tag mAb
PAtag/ MAPtag/ RAPtag/ BAPtag/ Histag/ LPtag/ MBPtag/ RIEDLtag
CasMab
PDPN/ PODXL/ CD44s/ CD44v3/ CD44v5/ CD44v6/ CD44v7/ EpCAM/ TROP2/ EGFR/ HER2/ HER3
Clinically used humanized/human mAb
Bamlanivimab/ Bebtelovimab/ Bivatuzumab/ Casirivimab/ Cilgavimab/ Datopotamab/ Sacituzumab/ Trastuzumab
anti-dog mAb
EGFR/EGFR-HER2/HER2/PD-L1/PDPN
control IgG (in vivo grade)
mouse IgG2a / mouse IgG2a
ACKR1/ ATRX/ CA4/ CCR1/ CCR2/ CCR3/ CCR4/ CCR5/ CCR6/ CCR8/ CCR9/ CCR11/ CD10/ CD19/ CD20/ CD39/ CD44s/ CD44v3/ CD44v4/ CD44v5/ CD44v6/ CD44v7/ CD44v8/ CD44v9/ CD44v10/ CD133/ CD271/ CD273/ CD274/ CD276/ CDH1/ CXCR1/ CXCR2/ CXCR3/ CXCR4/ CXCR5/ CXCR6/ CXCR7/ DGK/ EGFR/ EpCAM/ EphA1/ EphA6/ EphA8/ EphB1/ EphB2/ EphB4/ EphB6/ GPC1/ GPC3/ HER2/ HER3/ HER4/ HGF/ IDH/ KLRG1/ PD-L1/ PD-L2/ PODXL/ PDPN (mouse; rat; rabbit; dog; bovine; cat; tiger; horse; pig; goat; alpaca; Tas_devil; bear; whale; sheep; sea_lion; elephant; ferret; hamster; giraffe; panda)/ RdRP/ SARS-CoV-2 (N/ S2/ bispecific)/ TERT/ TIGIT/ TROP2/XCR1
anti-Tag mAb
PAtag/ MAPtag/ RAPtag/ BAPtag/ Histag/ LPtag/ MBPtag/ RIEDLtag
CasMab
PDPN/ PODXL/ CD44s/ CD44v3/ CD44v5/ CD44v6/ CD44v7/ EpCAM/ TROP2/ EGFR/ HER2/ HER3
Clinically used humanized/human mAb
Bamlanivimab/ Bebtelovimab/ Bivatuzumab/ Casirivimab/ Cilgavimab/ Datopotamab/ Sacituzumab/ Trastuzumab
anti-dog mAb
EGFR/EGFR-HER2/HER2/PD-L1/PDPN
control IgG (in vivo grade)
mouse IgG2a / mouse IgG2a
Peptide tag system
| PA tag NZ-1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PA tag mAb NZ-1; rat IgG2a, lambda |
PAtag: GVAMPGAEDDVV; 12 amino acid; trademark: No. 5671624; from AMED_PDIS project | Purification, IP, IHC, WB, FACS | PEP2014;
JCS2016 PS2019; AC2021 Sci2022; Nature |
done |
Wako
|
| anti-PA tag mAb NZ-27; human IgG1, lambda |
PAtag: GVAMPGAEDDVV; 12 amino acid; trademark: No. 5671624; from AMED_PDIS project | Purification, IP, IHC, WB, FACS | JBC2023 | done |
|
| anti-PA14 tag mAb NZ-1; rat IgG2a, lambda |
PA14 tag: EGGVAMPGAEDDVV; from AMED_SentanBio | Purification, IP, IHC, WB, FACS |
PA14 tag system hGH-fusion Fab |
done | |
| anti-PA16 tag mAb NZ-1; rat IgG2a, lambda |
PA16 tag: GLEGGVAMPGAEDDVV; from AMED_SentanBio | Purification, IP, IHC, WB, FACS | C44Mab5; PMab202; PMab210; PMab213; PMab219; PMab233 | done | |
| MAP tag PMab-1 | Character | Application | Ref | Gene cloning | Company |
| anti-MAP tag mAb PMab-1: rat IgG2a, kappa--> PAtag |
MAPtag (GDGMVPPGIEDK; 12 amino acids); trademark: No. 5988384; from AMED_KakushinBio; press release | Purification, IP, IHC, WB, FACS | MAB2016 BBREP2018 JB2020 |
done |
AA; abcam; Nov; Merck; BioLegend BD (coming soon) |
| anti-MAP16 tag mAb (PMab-1; rat IgG2a, kappa) |
MAP16 tag: PGTGDGMVPPGIEDKI; 16 amino acids; from AMED_Tousa | Purification, IP, IHC, WB, FACS | PMab-235
PMab-44_goat |
done | BD (coming soon) |
| RAP tag PMab-2 | Character | Application | Ref | Gene cloning | Company |
| anti-RAP tag mAb (PMab-2; mouse IgG1, kappa)--> PAtag |
RAP tag: DMVNPGLEDRIE; 12 amino acids; from AMED_KakushinBio | Purification, IP, IHC, WB, FACS | MAB2017 FPS2020 PP2021 |
done |
AA;
abcam Merck; BioLegend |
| anti-RAP14 tag mAb (double tag) (PMab-2; LpMab-7) |
RAP14 tag (DMVNPGLEDRIEDL; 14 amino acids); from AMED_Tousa | Purification, IP, IHC, WB, FACS | PMab44; PMab256; PDF; PMab253 | done | |
| anti-RAP16 tag mAb (PMab-2; mouse IgG1, kappa) |
RAP16 (GPGDDMVNPGLEDRIE; 16 amino acids); from AMED_SentanBio | Purification, IP, IHC, WB, FACS | PMab-225_alpaca
PMab-225_epitope PMab-44_alpaca |
done | |
| RIEDL tag LpMab-7 | Character | Application | Ref | Gene cloning | Company |
| anti-RIEDL tagmAb (LpMab-7; mouse IgG1, kappa)-->PAtag |
RIEDLtag (RIEDL; 5 amino acids): from AMED_SentanBio | Purification, IP, IHC, WB, FACS | RIEDL; PMab237 (1); PMab237 (2); C44-5; C44-46; E134; E51 | done | abcam |
| MBP tag TMab-2 | Character | Application | Ref | Gene cloning | Company |
| anti-MBP tag mAb (TMab-2; rat IgG2b, kappa) |
specific for maltose-binding protein | IHC, WB | PubMed
|
done | |
| anti-MBP tag mAb (YM-2;rat IgG2b, kappa) |
specific for maltose-binding protein | IHC, WB | PubMed
|
done | BioLegend |
| BAP tag PMab-44 | Character | Application | Ref | Gene cloning | Company |
| anti-BAP tagmAb (PMab-44; mouse IgG1, kappa)--> PAtag |
BAP tag(EKTTLGVEDYTTTPAA; 16 amino acids); from AMED_BINDS_SentanBio | Purification, IP, IHC, WB, FACS | PMab247 PMab241 |
done | Zenogen |
| LP tag LpMab-17 | Character | Application | Ref | Gene cloning | Company |
| anti-LP tag mAb (LpMab-17; mouse IgG1, kappa)-->PAtag |
LPtag (NSVTGIRIEDLPTSES; 16 amino acids); from AMED_BINDS_SentanBio | Purification, IP, IHC, WB, FACS | PMab52 PMab231 |
done |
BD Merck |
| His tag HisMab-1 | Character | Application | Ref | Gene cloning | Company |
| anti-His tag (HisMab-1;mouse IgG2b, kappa)-->PAtag | His tag (HHHH; 4 amino acids); from AMED_SentanBio; Kd: 4.4 x 10^-9 M | Purification, IP, IHC, WB, FACS |
C20Mab60 Rituximab C20Mab11 |
done | |
| anti-His tag (HisMab-1-hG1; human IgG1, kappa) | His tag (HHHH; 4 amino acids); from AMED_SentanBio | Purification, IP, IHC, WB, FACS | done | ||
| anti-His tag (HisMab-1-scFv-mG2a; mouse IgG2a) | scFv of HisMab-1; Kd: 6.6 x 10^-9 M | IHC, WB, FACS | done |
Chemokine receptor (summary)
| mouse CCR1 (CD191) | Character --> anti-human CCR1 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR1 mAb (C1Mab-1; rat IgG2b, lambda) | CBIS method; Kd: 1.5 x 10^-8 M ref: clone S15040E (BioLegend); rat IgG2b; Kd: 3.5 x 10^-8 M; no mAb from BD (summary) |
FACS, WB | |||
| anti-mouse CCR1 mAb (C1Mab-2; rat IgG2b, lambda) | CBIS method Kd: 3.9 x 10^-9 M |
FACS, WB | |||
| anti-mouse CCR1 mAb (C1Mab-4; rat IgG2b, kappa) | CBIS method Kd: 9.0 x 10^-9 M |
FACS, WB | |||
| anti-mouse CCR1 mAb (C1Mab-5; rat IgG2b, lambda) | CBIS method Kd: 1.2 x 10^-8 M |
FACS, WB | |||
| anti-mouse CCR1 mAb (C1Mab-6; rat IgG2b, kappa) | CBIS method Kd: 3.9 x 10^-9 M |
FACS, WB | C1Mab-6 |
| mouse CCR2 (CD192) | Character --> anti-human CCR2 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR2 mAb (C2Mab-6; rat IgG1, kappa) |
ref: clone EPR20844-15 (abcam); rabbit IgG
ref: clone 475301 (BD); rat IgG2b ref: clone SA203G11 (BioLegend); rat IgG2b |
FACS, WB, ICC |
C2Mab-6 epitope (summary) |
done |
| mouse CCR3 (CD193) | Character --> anti-human CCR3 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR3 mAb(C3Mab-2; rat IgG2b, kappa) |
specific for mouse CCR3; established by CBIS method (summary) | FACS |
C3Mab-2 ICC |
done | |
| anti-mouse CCR3 mAb (C3Mab-3; rat IgG2a, kappa0 | specifc mouse CCR3; established by CBIS method | FACS |
C3Mab-3 epitope |
done | |
| anti-mouse CCR3 mAb (C3Mab-4; rat IgG2a, kappa) | specific mouse CCR3; established by CBIS method | FACS | epitope | done | |
| anti-mouse CCR3 mAb (C3Mab-6; rat IgG1, kappa) | specific mouse CCR3; peptide immunization | FACS |
C3Mab-6 epitope |
done | |
| anti-mouse CCR3 mAb (C3Mab-7; rat IgG1, kappa) | specific mouse CCR3; peptide immunization | FACS |
C3Mab-7 epitope-1 epitope-2 |
done |
| mouse CCR4 (CD194) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR4 mAb (C4Mab-1; rat IgG1, kappa) | specific for mouse CCR4; peptide immunization
2G12 (BioLegend); hamster IgG no mAb from BD (summary) |
FACS |
C4Mab-1 epitope |
done | |
| anti-mouse CCR4 mAb (C4Mab-1-mG2a-f; mIgG2a,k) | specific for mouse CCR4 | FACS | done |
| mouse CCR5 (CD195) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR5 mAb (C5Mab-1; rat IgM, kappa) | specific for CCR5 (by CBIS method) ; ref: clone C34-3448 (BD); rat IgG2c; ref: clone HM-CCR5 (BioLegend); hamster (Kd: 1.6 x 10^-7) (summary) | FACS | done | ||
| anti-mouse CCR5 mAb (C5Mab-2; rat IgG2b, kappa) | specific for CCR5 by CBIS method (Kd: 4.3 x 10^-8) |
FACS | accept | done | |
| anti-mouse CCR5 mAb (C5Mab-3; rat IgG2b, kappa) | specific for CCR5 by CBIS method (Kd: 5.8 x 10^-8) |
FACS | done | ||
| anti-mouse CCR5 mAb (C5Mab-4; rat IgG2a, kappa) | specific for CCR5 by peptide immunization (Kd: 3.5 x 10^-8) immunogen: MDFQGSVPTYSYDIDYGMS |
FACS, WB | in preparation | ||
| anti-mouse CCR5 mAb (C5Mab-5; rat IgG2a, kappa) | specific for CCR5 by peptide immunization (Kd: 8.1 x 10^-8) immunogen: MDFQGSVPTYSYDIDYGMS |
FACS, WB | |||
| anti-mouse CCR5 mAb (C5Mab-7; rat IgG1, kappa) | specific for CCR5 by peptide immunization immunogen: MDFQGSVPTYSYDIDYGMS |
FACS | |||
| anti-mouse CCR5 mAb (C5Mab-8; rat IgG1, kappa) | specific for CCR5 by peptide immunization (Kd: 7.3 x 10^-9) immunogen: MDFQGSVPTYSYDIDYGMS |
FACS, WB | in preparation |
| mouse CCR6 (CD196) | Character --> anti-human CCR6 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR6 mAb (C6Mab-9; rat IgG1, kappa) | specific for mouse CCR6; peptide immunization
ref: clone 29-2L17 (BioLegend); hamster IgG ref: clone 140706 (BD); rat IgG2a (summary) |
FACS | done | ||
| anti-mouse CCR6 mAb (C6Mab-9-mG2a-f; mIgG2a,k) | specific for mouse CCR6 | FACS | done | ||
| anti-mouse CCR6 mAb (C6Mab-10; rat IgG2a, kappa) | specific for mouse CCR6; peptide immunization | FACS, WB | |||
| anti-mouse CCR6 mAb (C6Mab-13; rat IgG1, kappa) | specific for mouse CCR6; peptide immunization | FACS |
C6Mab-13 epitope |
done |
| mouse CCR7 (CD197) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR7 mAb (C7Mab series) | in preparation |
| mouse CCR8 (CD198) | Character --> anti-human CCR8 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR8 mAb (C8Mab-1; rat IgG2a, kappa) |
clone SA214G2 (BioLegend); rat IgG2b no mAb from BD patent (Shionogi/Osaka Univ.) (summary) |
FACS, ICC | C8Mab-1 | done | |
| anti-mouse CCR8 mAb (C8Mab-2; rat IgG2b, kappa) |
specific mouse CCR8; established by CBIS method | FACS, ICC |
C8Mab-2 ICC epitope |
done | Merck |
| anti-mouse CCR8 mAb (C8Mab-2-mG2a) | specific mouse CCR8; established by CBIS method | FACS, ICC | done |
|
|
| anti-mouse CCR8 mAb (C8Mab-3; rat IgG1, kappa) |
specific mouse CCR8; established by CBIS method | FACS, ICC | C8Mab-3 | done |
| mouse CCR9 (CD199) | Character --> anti-human CCR9 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR9 mAb (C9Mab-24; rat IgG2a, kappa) | peptide immunization (summary) ref: clone 9B1 (BioLegend; BD); rat IgG2a ref: clone CW-1.2 (BioLegend; BD); mouse IgG2a |
FACS, WB |
C9Mab-24 epitope |
done |
| mouse CCR10 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR10 mAb (C10Mab series) |
CBIS method
(summary) ref: clone 248918R (R&D); rat IgG2a |
FACS | Li et al |
| mouse CCR11 (ACKR4, CCRL1) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR11 mAb (C11Mab-1; rat IgG2b, kappa) |
peptide immunogen: MALELNQSAEYYYEENEMNC Kd: 3.5 x 10^-9 |
FACS, WB(weak) | |||
| anti-mouse CCR11 mAb (C11Mab-2; rat IgG2b, kappa) | peptide immunogen: MALELNQSAEYYYEENEMNC | FACS, WB | in preparation (Ouchida et al) |
||
| anti-mouse CCR11 mAb (C11Mab-3; rat IgG2b, kappa) | specific for CCR11(ACKR4) peptide immunization immunogen: MALELNQSAEYYYEENEMNC |
FACS |
| mouse CXCR1 (CD181) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR1 mAb (Cx1Mab-1; rat IgG1, kappa) | Kd: 2.6 x 10^-9 M (summary) ref: clone 1122A (R&D); rabbit IgG; Kd: 2.7 x 10^-9 M; clone U45-632 (BD); rat IgG2b |
FACS, WB | Cx1Mab-1 | done | |
| anti-mouse CXCR1 mAb (Cx1Mab-2; rat IgG1, kappa) | Kd: 2.0 x 10^-9 M peptide immunization |
FACS WB (weak) |
|||
| anti-mouse CXCR1 mAb (Cx1Mab-3; rat IgG2a, kappa) | Kd: 6.2 x 10^-10 M peptide immunization |
FACS WB (weak) |
|||
| anti-mouse CXCR1 mAb (Cx1Mab-4; rat IgG1, kappa) | Kd: 2.1 x 10^-9 M peptide immunization |
FACS | |||
| anti-mouse CXCR1 mAb (Cx1Mab-5; rat IgG2a, kappa) | Kd: 8.2 x 10^-9 M peptide immunization |
FACS, WB | |||
| anti-mouse CXCR1 mAb (Cx1Mab-6; rat IgG1, kappa) | Kd: 1.0 x 10^-9 M peptide immunization |
FACS | |||
| anti-mouse CXCR1 mAb (Cx1Mab-7; rat Ig2b, kappa) | Kd: 8.1 x 10^-9 M peptide immunization |
FACS | |||
| anti-mouse CXCR1 mAb (Cx1Mab-8; rat Ig2b, kappa) | Kd: 3.0 x 10^-10 M peptide immunization |
FACS | in preparation (Li G et al) |
| mouse CXCR2 (CD182) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR2 mAb (Cx2Mab-1; rat IgG2b, kappa) | peptide immunization ref: BioLegend (summary) |
FACS | in preparation (Tanaka et al) | ||
| anti-mouse CXCR2 mAb (Cx2Mab-2; rat IgG2b, kappa) | peptide immunization | FACS |
| mouse CXCR3 (CD183) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR3 mAb (Cx3Mab-2; rat IgG2b, kappa) | specific for mouse CXCR3 Kd: 5.9 x 10^-9 M (summary) |
FACS | done | ||
| anti-mouse CXCR3 mAb (Cx3Mab-4; rat IgG1, kappa) | Kd: 1.3 x 10^-9 M
ref: clone: CXCR3-173 (BD; BioLegend); hamster IgG; Kd: 1.3 x 10^-9 M |
FACS | Cx3Mab-4 | done | |
| anti-mouse CXCR3 mAb (Cx3Mab-5; rat IgG2c, kappa) | specific for mouse CXCR3 Kd: 5.3 x 10^-9 M |
FACS | done | ||
| anti-mouse CXCR3 mAb (Cx3Mab-6; rat IgG2b, kappa) | specific for mouse CXCR3 Kd: 4.5 x 10^-9 M |
FACS | x |
| mouse CXCR4 (CD184) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR4 mAb (Cx4Mab-1; rat IgG2a, kappa) | specific for mouse CXCR4 (summary)
ref: clone 2B11/CXCR4 (BD); rat IgG2b ref: clone L276F12 (BioLegend); rat IgG2b |
FACS | Cx4Mab-1 | done |
| mouse CXCR5 (CD185) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR5 mAb (Cx5Mab-2; rat IgG2a, kappa) | peptide immunization (summary) ref: clone 2G8 (BD) ; ref: clone L138D7 (BioLegend) Kd: 7.0 x 10^-9 |
FACS | |||
| anti-mouse CXCR5 mAb (Cx5Mab-3; IgG2b, kappa) | peptide immunization Kd: 7.2 x 10^-10 |
FACS | in preparation (Ishikawa et al) | ||
| anti-mouse CXCR5 mAb (Cx5Mab-4; IgM, kappa) | peptide immunization | FACS |
| mouse CXCR6 (CD186) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR6 mAb(Cx6Mab-1; rat IgG1, kappa) | specific for mouse CXCR6 peptide immunization (summary) |
FACS, WB |
Cx6Mab-1 epitope-1 epitope-2 |
done | |
| anti-mouse CXCR6 mAb(Cx6Mab-5; rat IgG1, kappa) | specific for mouse CXCR6 peptide immunization |
FACS, WB | done |
| mouse CXCR7 (CD187, ACKR3) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR7 mAb (Cx7Mab-1; rat IgG2a, kappa) | specific for mouse CXCR7 (summary) |
FACS | in preparation (Tanaka et al) |
| mouse ACKR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse ACKR1 mAb | specific for ACKR1 ref |
FACS |
| mouse ACKR2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse ACKR2 mAb | specific for ACKR2 | FACS |
| mouse ACKR3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse ACKR3 mAb | also known as CXCR7 | FACS |
| mouse ACKR5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse ACKR5 mAb | also known as CCRL2 ref: clone S21013E (BioLegend) |
FACS |
| mouse XCR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mXCR1 mAb | in preparation | FACS |
| mouse CX3CR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CX3CR1 mAb | in preparation ref: clone SA011F11 (BioLgend): mouse IgG2a ref: clone Z8-50 (BD): rat IgG2a |
FACS |
| human CCR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR1 mAb |
in preparation |
| human CCR2 (CD192) | Character --> anti-mouse CCR2 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR2 mAb (C2Mab-9; mouse IgG1, kappa) |
specific for human CCR2; expressed in U937 or NK cell; peptide immunization | FACS, ICC |
C2Mab-9 epitope |
done |
| human CCR3 | Character --> anti-mouse CCR3 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR3 mAb (C3Mab-8; mouse IgG1, kappa)
|
specific for human CCR3 peptide immunization; Kd: 5.0 x 10^-9 M ref: 5E8 (BioLegend); Kd: 2.5 x 10^-9 M |
FACS, WB |
| human CCR4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR4 mAb |
in preparation |
| human CCR5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR5 mAb |
in preparation |
| human CCR6 (CD196) | Character --> anti-mouse CCR6 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR6 mAb (C6Mab-19; mouse IgG1, kappa) | specific for human CCR6; expressed in HepG2 or HuH-7; peptide immunization |
FACS, IHC, ELISA | C6Mab-19 |
| human CCR7 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR7 mAb |
in preparation |
| human CCR8 | Character --> anti-mouse CCR8 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR8 mAb (C8Mab-20; mouse IgG1, kappa) |
specific for human CCR8 peptide immunization ref: S19017D, L263G8 (BioLegend); 433H (BD) |
FACS | in preparation (Tanaka et al) | ||
| anti-hCCR8 mAb (C8Mab-21; mouse IgM, kappa) | specific for human CCR8 CBIS method Kd: 6.5 x 10^-8 M |
FACS | C8Mab-21 |
| human CCR9 (CD199) | Character --> anti-mouse CCR9 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR9 mAb (C9Mab-1; mouse IgG1, kappa) | specific for human CCR9; developmed by CBIS method; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS |
C9Mab-1;
epitope ICC |
done |
BD;
exbio Novus Thermo |
| anti-hCCR9 mAb (C9Mab-6; mouse IgG1, kappa) | specific for human CCR9; established by CBIS method; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-8; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-9; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-10; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-11; mouse IgG2a, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS, WB |
C9Mab-11 epitope |
done | |
| anti-hCCR9 mAb (C9Mab-12; mouse IgG1, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-13; mouse IgG2a, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-14; mouse IgG1, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-1016; mouse IgG1, kappa) |
specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | SunRock | |
| anti-hCCR9 mAb (C9Mab-17; mouse IgG2b, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-18; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-1019; mouse IgG1, kappa) |
specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | SunRock | |
| anti-hCCR9 mAb (C9Mab-21; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done |
| human CCR10 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR10 mAb |
in preparation |
| human CCR11 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR11 mAb |
in preparation |
| human CXCR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR1 mAb |
in preparation |
| human CXCR2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR2 mAb |
in preparation |
| human CXCR3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR3 mAb |
in preparation |
| human CXCR4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR4 mAb |
in preparation |
| human CXCR5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR5 mAb |
in preparation |
| human CXCR6 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR6 mAb |
in preparation |
| human CXCR7 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR7 mAb |
in preparation |
| human XCR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hXCR1 mAb (X1Mab-4; mouse IgG1, kappa) | specific for human XCR1; established by peptide immunization | FACS | done | ||
| anti-hXCR1 mAb (X1Mab-29; mouse IgM, kappa) | specific for human XCR1; established by peptide immunization | FACS | done | ||
| anti-hXCR1 mAb (X1Mab-47; mouse IgM, kappa) | specific for human XCR1; established by CBIS (immunization of MDA-MB-157/PA-hXCR1) | FACS |
EGFR/HER2/HER3/HER4
| mouse EGFR domain-I | Character --> human EGFR | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EGFR mAb; EMab-300 (rat IgG1, kappa) | specific for mouse EGFR | FACS | EMab-300 | done | |
| mouse EGFR domain-II | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb; EMab-301 (rat IgM, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-301-mG2a-f (rat IgG2a, kappa) | specific for mouse EGFR | FACS | |||
| mouse EGFR domain-III | Character | Application | Ref | Gene cloning | Company |
| anti-mouse/human EGFR mAb; EMab-88 (mouse IgG1, kappa) | specific for EGFR; EMab-88 was developed against human EGFR; crossreacts with mouse EGFR (domain-III) | FACS | data | done | |
| human EGFR domain-I | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (EMab-23; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-I | FACS | done | ||
| anti-EGFR mAb (EMab-78; mouse IgG2b, kappa) |
specific for EGFR; reacts with domain-I | FACS | done | ||
| anti-EGFR mAb (EMab-129; mouse IgG1, lambda) |
specific for EGFR; reacts with domain-I | FACS | done | ||
| human EGFR domain-II | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (EMab-19; mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-II | FACS | done | ||
| anti-EGFR mAb (EMab-33; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-II | FACS | done | ||
| anti-EGFR mAb (EMab-57; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-II | FACS | done | ||
| anti-EGFR mAb (EMab-76; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-II | FACS | done | ||
| human EGFR domain-III | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (EMab-134; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC | EMab-134
epitope-1; -2 AirID |
done |
abcam BD |
| anti-EGFR mAb (134-mG2a; mouse IgG2a, kappa) |
mouse IgG2a version of EMab-134; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC/CDC, antitumor activities | 134-mG2a | done | |
| anti-EGFR mAb (EMab-51; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC | EMab-51 epitope |
done | |
| anti-EGFR mAb (51-mG2a; mouse IgG2a, kappa) |
mouse IgG2a version of EMab-51specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | done | ||
| anti-EGFR mAb (51-mG2a-f; mouse IgG2a, kappa) |
core fucose-deficient mouse IgG2a version of EMab-51; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | done | ||
| anti-EGFR mAb (EMab-17; mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, ADCC/CDC, antitumor activities | EMab-17 metastasis |
done | |
| anti-EGFR mAb (recEMab-17-f; mouse IgG2a) |
core fucose-deficient mouse IgG2a version of EMab-17; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, ADCC/CDC, antitumor activities | done | ||
| anti-EGFR mAb (EMab-1; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
| anti-EGFR mAb (EMab-32; mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
| anti-EGFR mAb (EMab-114; mouse IgG2b, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
| anti-EGFR mAb (EMab-125; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB | done | ||
| anti-EGFR mAb (EMab-139; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB | done | ||
| anti-EGFR mAb (EMab-151; mouse IgG2b, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
| human EGFR domain-IV | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (EMab-95; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-IV | FACS | done | ||
| anti-EGFR mAb (EMab-110; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-IV | FACS | done | ||
| dog EGFR | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (134-mG2a-f; mouse IgG2a) |
core fucose-deficient mouse IgG2a version of EMab-134; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | CHO/dEGFR OS; Fibro Mammary |
done | |
| anti-EGFR mAb (E134Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of EMab-134; specific for EGFR | FACS, WB, IHC, ADCC, CDC, antitumor activities | Mammary Fibro & Osteo |
done | |
| bispecific | Character | Application | Ref | Gene cloning | Company |
| anti-dog EGFR-dog HER2 mAb (E134B-H77scFv-f) |
bispecific mAb for EGFR and HER2 | FACS, WB, IHC, ADCC, CDC, antitumor activities | E134B-H77scFv-f | done | |
| anti-EGFR-PDPN mAb (E134-NZ1scFv-mG2a-f) |
bispecific mAb for EGFR and PDPN | FACS, WB, IHC, ADCC, CDC, antitumor activities | done |
| mouse HER2 (CD340) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb (H2Mab-300 ; rat IgG2b, kappa) |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS | H2Mab-300 | done | |
| anti-HER2 mAb (H2Mab-303 ; rat IgG2a, kappa) |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS | done | ||
| anti-HER2 mAb (H2Mab-304 ; rat IgG1, kappa) |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS, WB | H2Mab-304 | done | |
| anti-HER2 mAb (H2Mab-307 ; rat IgG2a, kappa) |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS | done | ||
| anti-HER2 mAb (H2Mab-314 ; rat IgG1, kappa) |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS, WB | done | ||
| HER2 domain-I | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-77; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2; (ref: TNBC) | FACS, WB, IHC | H2Mab-77 | done | BioLegnd |
| anti-HER2 mAb (H2Mab-77-mG2a-f; mouse IgG2a) |
specific for HER2; crossreacts with dog HER2; (ref: TNBC) | FACS, WB, IHC | 77-mG2a-f | done | |
| anti-HER2 mAb (H2Mab-77-hG1; human IgG1) |
specific for HER2; crossreacts with dog HER2; (ref: TNBC) | FACS, WB, IHC | done | ||
| anti-HER2 mAb (H2Mab-119; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | H2Mab-119 structure H2Mab-250 |
done | |
| anti-HER2 mAb (H2Mab-119-mG2a-f; mouse IgG2a) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | 119-mG2a-f | done | |
| anti-HER2 mAb (H2Mab-119-hG1; human IgG1) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | done | ||
| anti-HER2 mAb (H2Mab-139; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | H2Mab-139 | done | abcam |
| anti-HER2 mAb (H2Mab-139-mG2a;mouse IgG2a) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | done | ||
| anti-HER2 mAb (H2Mab-139-mG2a-f; mouse IgG2a) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | 139-mG2a-f | done | |
| HER2 domain-II | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-32; mouse IgG1, kappa) |
specific for HER2 | FACS |
|
done | |
| anti-HER2 mAb (H2Mab-133; mouse IgG1, kappa) |
specific for HER2 | FACS |
|
done | |
| anti-HER2 mAb (H2Mab-193; mouse IgG1, kappa) |
specific for HER2 | FACS | H2Mab-250 | done | |
| anti-HER2 mAb (H2Mab-215; mouse IgG1, kappa) |
specific for HER2 | FACS | H2Mab-250 | done | |
| HER2 domain-III | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-19; mouse IgG2b, kappa) |
specific for HER2; crossreacts with mouse HER2 or dog HER2; domain-III | FACS, ADCC/CDC, antitumor activities | PC
CRC GBM |
done | |
| anti-HER2 mAb (H2Mab-181; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2; domain-III; epitope: p373-392 | FACS, WB, IHC | H2Mab-181 epitope |
done | |
| HER2 domain-IV | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-41; mouse IgG2b, kappa) |
specific for HER2; crossreacts with dog HER2; domain-IV | FACS, antitumor activities | H2Mab-41
dogHER2 |
done | |
| anti-HER2 mAb (trastuzumab; human IgG1,kappa) |
specific for HER2 | FACS | H2Mab-250 H2Mab-214 |
done | |
| anti-HER2 mAb (trastuzumab-f; human IgG1,kappa) |
defucosylated trastuzumab; specific for HER2 | FACS |
250_in vivo |
done | |
| anti-HER2 mAb (tras-mG2a-f; mouse IgG2a,kappa) |
specific for HER2 mouse IgG2a-version of trastuzumab defucosylated |
FACS | 250_in vivo | done | |
| anti-HER2 mAb (H77Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of H2Mab-77 | FACS, WB, IHC, ADCC/CDC, antitumor activities | H77Bf OS fibro |
done |
| HER3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti HER3 mAb (H3Mab-17; mouse IgG2a, kappa) |
specific for HER3 | FACS, ADCC/CDC, antitumor activities | H3Mab-17 | done | exbio |
| HER4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER4 mAb (H4Mab-12; mouse IgG2a, kappa) | Kd: 3.1 x 10^-10 M for T-47D ref: clone P6-1 (BD; CosmoBio: rat IgG2a; Kd: 2.8 x 10^-10 M for T-47D) |
FACS | done | ||
| anti-HER4 mAb (H4Mab-16; mouse IgG1, kappa) | immunization of LN229/HER4 Kd: 1.2 x 10^-9 M for T-47D |
FACS | done |
Immune checkpoint
| KLRG1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-KLRG1 mAb (KLMab-1; mouse IgG1, kappa) |
specific for human KLRG1 | FACS, ICC | KLMab-1 ICC |
done |
| PD-L1 (CD274/B7H1) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PD-L1 mAb (L1Mab-13; mouse IgG1, kappa) |
specific for human PD-L1 | FACS, WB, IHC (cell), IHC (tissue), ELISA | L1Mab-13 | done | |
| anti-PD-L1 mAb (13-mG2a-f; mouse IgG2a, kappa) |
specific for human PD-L1; core fucose-deficient IgG2a of L1Mab-13 | FACS, WB, IHC (cell), IHC (tissue), ELISA, ADCC/CDC, antitumor activities | 13-mG2a-f | done | |
| dog PD-L1 | Character | Application | Ref | Gene cloning | Company |
| anti-dog PD-L1 mAb (L1Mab-347; mouse IgG1, kappa) |
specific for dog PD-L1 (extracellular domain) | FACS, IHC | done | ||
| anti-dog PD-L1 mAb (L1Mab-352; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-352 | done | |
| anti-dog PD-L1 mAb (L1Mab-354; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-354 | done |
| PD-L2 (CD273/B7H2) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PD-L2 mAb (L2Mab-1; mouse IgG2b, kappa) |
specific for PD-L2 | FACS, WB, IHC (cell) | done |
| TIGIT | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-TIGIT mAb (TgMab-1; mouse IgG1, kappa) |
specific for TIGIT | FACS KD: 6.7 x 10^-10 |
done | ||
| anti-TIGIT mAb (TgMab-2; mouse IgG1, kappa) |
specific for TIGIT | FACS, WB, ICC KD: 3.5 x 10^-9 |
TgMab-2 ICC |
done | BD |
Monoclonal antibodies for the other membrane proteins
| CA4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CA4 mAb (CA4Mab-1; rat IgG1, kappa) |
specific for mouse carbonic anhydrase IV (CA4) | FACS, ELISA | done | ||
| anti-CA4 mAb (CA4Mab-2; rat IgG1, kappa) |
specific for mouse carbonic anhydrase IV (CA4) | FACS, ELISA | done |
| CD10 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD10 mAb (C10Mab-31; mouse IgG1, kappa) |
specific for CD10; CBIS method | FACS | C10Mab-31 RCC |
done |
| CD19 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD19 mAb (C19Mab-1; mouse IgG1, kappa) |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | C19Mab-1 | done | |
| anti-CD19 mAb (C19Mab-2; mouse IgG1,kappa) | specific for CD19; CBIS method; LN229/CD19 immunization | FACS | done | ||
| anti-CD19 mAb (humC19Mab-2; human IgG1,kappa) | humanized C19Mab-2 | FACS | done | ||
| anti-CD19 mAb (humC19Mab-2 -scFv) |
scFv of humanized C19Mab-2 | FACS | done | ||
| anti-CD19 mAb (C19Mab-3; mouse IgG1, kappa) |
specific for CD19; CBIS method; ectodomain of CD19 immunization | IHC,WB | C19Mab-3 | done |
| CD20 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD20 mAb (C20Mab-11; mouse IgM, kappa) |
specific for CD20 | FACS, WB, IHC |
C20Mab-11 epitope |
ongoing | |
| anti-CD20 mAb (C20Mab-60; mouse IgG2a, kappa) |
specific for CD20; ref: rituximab | FACS, WB, IHC |
C20Mab-60 epitope-1 epitope-2 |
ongoing | BioLegnd |
| CD39 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD39 mAb (C39Mab-1; rat IgG2a, kappa) |
specific for mouse CD39 | FACS, WB |
C39Mab-1
epitope |
done | |
| anti-CD39 mAb (C39Mab-1-ratM; rat IgM, kappa) |
specific for mouse CD39 | FACS, WB | done | ||
| anti-CD39 mAb (C39Mab-2; rat IgG2a, lambda) |
specific for mouse CD39 | FACS | C39Mab-2 | done |
| CD44s | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44s mAb (C44Mab-5; mouse IgG1, kappa) |
Specific for CD44s (CD44 standard) | IHC, FACS, WB | C44Mab-5 epitope |
done | abcam BioLegnd |
| anti-CD44s mAb (5-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-5; specific for CD44s (CD44 standard) | IHC, FACS, ADCC, CDC, antitumor activities | 5-mG2a-f | done | |
| anti-CD44s mAb (C44Mab-46; mouse IgG1, kappa) |
specific for CD44s (CD44 standard) | FACS, IHC, WB | C44Mab-46 epitope-1 epitope-2 |
done | |
| anti-CD44s mAb (C44Mab-46-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-46 specific for CD44s (CD44 standard) |
IHC, FACS, WB | C44Mab-46-mG2a-f | done |
| CD44v3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44v3 mAb (C44Mab-6; mouse IgG1, kappa) |
specific for CD44v3 (oral cancer and colon cancer) |
FACS, WB, IHC, ELISA | C44Mab-6(IJMS) FACS(CAS) |
done | |
| anti-CD44v3 mAb (C44Mab-6-mG2a-f; mouse IgG2a) |
IgG2a version of C44Mab-6 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| CD44v4 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v4 mAb (C44Mab-108; mouse IgG1, kappa) |
specific for CD44v4 (oral cancer) |
WB, IHC, ELISA | C44Mab-108 epitope |
done | |
| anti-CD44v4 mAb (C44Mab-112; mouse IgG1, kappa) |
specific for CD44v4 crossreact with mouse CD44 |
WB, IHC, ELISA | done | ||
| anti-CD44v4 mAb (C44Mab-118; mouse IgG1, kappa) |
specific for CD44v4 crossreact with mouse CD44 |
WB, IHC, ELISA | done | ||
| CD44v5 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v5 mAb (C44Mab-3; mouse IgG1, kappa) |
specific for CD44v5 (pancreatic cancer) |
FACS, WB, IHC, ELISA | C44Mab-3 (antibodies) |
done | |
| anti-CD44v5 mAb (C44Mab-3-mG2a-f; mouse IgG2a) |
IgG2a version of C44Mab-3 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| CD44v6 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v6 mAb (C44Mab-9; mouse IgG1, kappa) |
specific for CD44v6 (colon cancer) |
FACS, WB, IHC, ELISA | C44Mab-9 (IJMS) |
done | |
| anti-CD44v6 mAb (C44Mab-9-mG2a-f; mouse IgG2a) |
IgG2a version of C44Mab-9 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| anti-CD44v6 mAb (bivatuzumab; human IgG1, kappa) |
specific for CD44v6 | ref | done | ||
| anti-CD44v6 mAb (biva-mG2a-f; mouse IgG2a, kappa) |
specific for CD44v6 mouse IgG2a type defucosylated |
||||
| CD44v7 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v7/v8 mAb (C44Mab-34; mouse IgG1, kappa) |
specific for CD44v7/v8 (oral cancer) |
FACS, WB, IHC, ELISA | C44Mab-34 (Biomedicines) |
done | |
| anti-CD44v7/v8 mAb (C44Mab-34-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-34 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| CD44v8 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v8 mAb (C44Mab-94; mouse IgG1, kappa) |
specific for CD44v8 (gastric cancer) |
FACS, WB, IHC, ELISA | C44Mab-94 (antibodies) |
done | |
| anti-CD44v8 mAb (C44Mab-94-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-94 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| CD44v9 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v9 mAb (C44Mab-1; mouse IgG1, kappa) |
specific for CD44v9 (colon cancer) |
FACS, WB, IHC, ELISA | C44Mab-1(CIMB) FACS(CAS) |
done | |
| anti-CD44v9 mAb (C44Mab-1-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-1 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| CD44v10 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v10 mAb (C44Mab-18; mouse IgM, kappa) |
specific for CD44v10 (oral cancer) |
FACS, WB, IHC, ELISA | C44Mab-18 (CIMB) |
done | |
| anti-CD44v10 mAb (C44Mab-18-mG1; mouse IgG1, kappa) |
mouse IgG1 version of CD44v10 | FACS, WB, IHC, ELISA | done | ||
| anti-CD44v10 mAb (C44Mab-18-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-18 | FACS, WB, IHC, ELISA | ongoing | done |
| CD73 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD73 mAb | in preparation | FACS |
| CD133 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD133 mAb (CMab-43; mouse IgG2a, kappa) |
specific for CD133 | FACS, WB, IHC, ADCC/CDC, antitumor activities |
CMab-43 in vivo |
done |
abcam BD |
| anti-CD133 mAb (CMab-44; mouse IgG1, kappa) |
specific for CD133; detects AML |
FACS, WB | done |
| CD271 (NGFR) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD271 mAb (G4B1; mouse IgG2a, kappa) |
cancer-specific mAb for CD271 | FACS, WB, IHC | anti-CD271 mAb | done | Merck |
| CD273 (PD-L2/B7H2) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PD-L2 mAb | --> PD-L2 |
| CD274 (PD-L1/B7H1) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PD-L1 mAb | --> PD-L1 |
| CD276 (B7H3) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD276 mAb | specific for CD276 |
| CDH1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH1 mAb Ca1Mab series |
specific for CDH1 |
| CDH2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH2 mAb Ca2Mab series |
specific for CDH2 |
| CDH3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH3 mAb (Ca3Mab-13; mouse IgG1, kappa) | specific for human CDH3 | FACS, WB | done |
| CDH4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH4 mAb Ca4Mab series |
specific for CDH4 |
| CDH5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH5 mAb Ca5Mab series |
specific for CDH5 |
| CDH6 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH6 mAb Ca6Mab series |
specific for CDH6 |
| CDH7 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH7 mAb Ca7Mab series |
specific for CDH7 |
| CDH8 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH8 mAb Ca8Mab series |
specific for CDH8 |
| CDH9 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH9 mAb Ca9Mab series |
specific for CDH9 |
| CDH10 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH10 mAb Ca10Mab series |
specific for CDH10 |
| CDH11 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH11 mAb Ca11Mab series |
specific for CDH11 |
| CDH12 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH12 mAb Ca12Mab series |
specific for CDH12 |
| CDH13 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH13 mAb Ca13Mab series |
specific for CDH13 |
| CDH14 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH14 mAb Ca14Mab series |
specific for CDH14 |
| CDH15 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH15 mAb Ca15Mab series |
specific for CDH15 |
| CDH16 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH16 mAb Ca16Mab series |
specific for CDH16 |
| CDH17 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH17 mAb Ca17Mab series |
specific for CDH17 |
| CDH18 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH18 mAb Ca18Mab series |
specific for CDH18 |
| CDH19 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH19 mAb Ca19Mab series |
specific for CDH19 |
| CDH20 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH20 mAb Ca20Mab series |
specific for CDH20 |
| CDH21 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH21 mAb Ca21Mab series |
specific for CDH21 |
| CDH22 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH22 mAb Ca22Mab series |
specific for CDH22 |
| CDH23 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH23 mAb Ca23Mab series |
specific for CDH23 |
| CDH24 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH24 mAb Ca24Mab series |
specific for CDH24 |
| CDH25 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH25 mAb Ca25Mab series |
specific for CDH25 |
| mouse EpCAM (CD326) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EpCAM mAb (EpMab-160; rat IgG2b, kappa) |
specific for mouse EpCAM | FACS | in preparation (Li G et al) | ||
| anti-EpCAM mAb (EpMab-161; rat IgG2b, kappa) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-162; rat IgG2a, kappa) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-163; rat IgG2c, kappa) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-164; rat IgM, kappa) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-165; rat IgG2a, kappa) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-166; rat IgM, kappa) |
specific for mouse EpCAM crossreact with human EpCAM (only exogenous) |
FACS | |||
| anti-EpCAM mAb (EpMab-167; rat IgM, kappa) |
specific for mouse EpCAM | FACS | |||
| human EpCAM (CD326) | Character | Application | Ref | Gene cloning | Company |
| anti-EpCAM mAb (EpMab-16; mouse IgG2a, kappa) |
specific for EpCAM | FACS, WB, IHC | EpMab-16 (1)
EpMab-16 (2) |
done | merck |
| anti-EpCAM mAb (EpMab-37; mouse IgG1, kappa) |
specific for EpCAM | FACS, WB, IHC | EpMab-37 epitope |
done | |
| anti-EpCAM mAb (EpMab-37-mG2a-f; mouse IgG2a) |
specific for EpCAM | FACS, WB, IHC, ADCC, CDC, antitumor activities |
EpMab-37 (1) EpMab-37 (2) |
done | |
| anti-EpCAM mAb (EpMab-3; mouse IgG1, kappa) |
specific for EpCAM | FACS | done |
| EphA1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA1 mAb (Ea1Mab-55; mouse IgG1, kappa) |
specific for human EphA1 established by CBIS method |
FACS | done |
| EphA2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA2 mAb Ea2Mab series |
in preparation | (Satofuka, Suzuki et al) |
| EphA3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA3 mAb Ea3Mab series |
in preparation | (Hirose, Suzuki et al) |
| EphA4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA4 mAb Ea4Mab series |
in preparation | (Li et al) |
| EphA5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA5 mAb Ea5Mab series |
in preparation | (Li et al) |
| EphA6 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA6 mAb (Ea6Mab-1, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method no ref mAb |
FACS | in preparation (Li G et al) |
| EphA7 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA7 mAb Ea7Mab series |
in preparation | (Yamamoto, Tanaka et al) |
| EphA8 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA8 mAb (Ea8Mab-1, mouse Ig) |
specific for human EphA8 established by CBIS method no ref mAb |
FACS | in preparation (Ouchida et al) | ||
| anti-EphA8 mAb (Ea8Mab-2, mouse Ig) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-3, mouse Ig) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-4, mouse Ig) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-5, mouse Ig) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-6, mouse Ig) |
specific for human EphA8 established by CBIS method |
FACS |
| EphA10 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA10 mAb Ea10Mab series |
in preparation | (Ubukata, Suzuki et al) |
| EphB1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphB1 mAb Eb1Mab series |
in preparation | (Tanaka et al) |
| EphB2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphB2 mAb Eb2Mab-1 (mouse Ig) |
specific for human EphB2 ref: clone 2H9 (BD) |
FACS | in preparation (Ubukata, Hirose et al) |
||
| anti-EphB2 mAb Eb2Mab-2 (mouse Ig) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-3 (mouse Ig) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-4 (mouse Ig) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-5 (mouse Ig) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-6 (mouse Ig) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-7 (mouse Ig) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-8 (mouse Ig) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-9 (mouse Ig) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-10 (mouse Ig) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-11 (mouse Ig) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-12 (mouse Ig) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-13 (mouse Ig) |
specific for human EphB2 | FACS |
| EphB3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphB3 mAb Eb3Mab series |
in preparation | (Li et al) |
| EphB4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphB4 mAb (Eb4Mab-7, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method ref: clone ab279601 (abcam) |
FACS, WB, IHC | Eb4Mab-7 | done |
| EphB6 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphB6 mAb Eb6Mab-1 (mouse IgG1,kappa) |
specific for human EphB6 established by CBIS method |
FACS | in preparation (Tanaka et al) | ||
| anti-EphB6 mAb Eb6Mab-2 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-3 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS, WB | |||
| anti-EphB6 mAb Eb6Mab-4 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-5 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-6 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-7 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-8 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-9 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-10 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-11 (mouse IgM, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-12 (mouse Ig) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-13 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-14 (mouse IgG1(2b), kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-15 (mouse IgG1, lambda) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-16 (mouse IgG1(2b), kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-17 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-18 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-19 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS |
| GPC1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC1 mAb (G1Mab-1, mouse Ig) | in preparation | (Kaneko, Yamamoto et al) |
| GPC2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC2 mAb (G2Mab-1, mouse Ig) | in preparation |
| GPC3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC3 mAb (G3Mab-1; mouse IgG1, kappa) |
specific for human GPC3 ref: abcam |
FACS | done | ||
| anti-GPC3 mAb (humG3Mab-1; human IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| anti-GPC3 mAb (humG3Mab-1-scFv) |
specific for human GPC3 | FACS; for CAR-T | done | ||
| anti-GPC3 mAb (G3Mab-2; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| anti-GPC3 mAb (humG3Mab-2; human IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| anti-GPC3 mAb (humG3Mab-2-scFv-Fc) |
specific for human GPC3 | FACS; for CAR-T | done | ||
| anti-GPC3 mAb (G3Mab-3; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| anti-GPC3 mAb (humG3Mab-3; human IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| anti-GPC3 mAb (humG3Mab-3-scFv-Fc) |
specific for human GPC3 | FACS; for CAR-T | done | ||
| anti-GPC3 mAb (G3Mab-4; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | in preparation (Suzuki et al) | done | |
| anti-GPC3 mAb (G3Mab-4-mG1; mouse IgG1, kappa) |
specific for human GPC3 | FACS, WB | |||
| anti-GPC3 mAb (G3Mab-4-mG2a; mouse IgG2a, kappa) |
specific for human GPC3 | FACS, WB | |||
| anti-GPC3 mAb (G3Mab-7; mouse IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| anti-GPC3 mAb (G3Mab-8; mouse IgG2a, kappa) |
specific for human GPC3 | FACS | x |
| GPC4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC4 mAb (G4Mab-1, mouse Ig) | in preparation |
| GPC5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC5 mAb (G5Mab-1, mouse Ig) | in preparation |
| GPC6 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC6 mAb (G6Mab-1, mouse Ig) | in preparation |
| TROP2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-TROP2 mAb (TrMab-6; mouse IgG2b, kappa) |
specific for human TROP2; (ref: TNBC) | IHC, WB, FACS |
TrMab-6 MCF7 TNBC |
done |
exbio |
| anti-TROP2 mAb (TrMab-29; mouse IgG1, kappa) |
specific for human TROP2 | IHC, WB, FACS | TrMab-29 | done | merck |
| anti-TROP2 mAb (Datopotamab; humanized IgG1, kappa) |
Humanized mAb for DS-1062/Dato-DXd (Daiichi-Sankyo) | FACS | done | ||
| anti-TROP2 mAb (Sacituzumab; humanized IgG1, kappa) |
Humanized mAb (Sacituzumab govitecan; Trodelvy) | FACS | done |
| HGF | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HGF mAb (t8E4; mouse IgG1, kappa) |
specific for active HGF | WB, IHC |
SREP IJMS |
done | Merck |
| anti-HGF mAb (t5A11; mouse IgG1, kappa) |
specific for HGF | WB, IHC |
SREP IJMS |
done | |
| anti-HGF mAb (t1E4; mouse IgG2b, kappa) |
specific for HGF | neutralization |
SREP |
done |
| Podocalyxin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PODXL mAb (PcMab-47; mouse IgG1, kappa) |
specific for human PODXL | FACS, WB, IHC | PcMab-47 IHC_OSCC epitope |
done | abcam exbio |
| anti-PODXL mAb (47-mG2a; mouse IgG2a, kappa) |
IgG2a version of PcMab-47; specific for human PODXL | FACS, WB, IHC; ADCC/CDC, antitumor activities | 47-mG2a IHC_LK IHC_EC |
done | |
| anti-PODXL mAb (47-mG2a-f; mouse IgG2a, kappa) |
core fucose-deficient IgG2a version of PcMab-47; specific for human PODXL | FACS, WB, IHC; ADCC/CDC, antitumor activities | 47-mG2a-f | done | |
| anti-PODXL mAb (chPcMab-47; human IgG1) |
specific for human PODXL | FACS, WB, IHC | chPcMab-47 | done |
| human podoplanin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hPDPN mAb (NZ-1; rat IgG2a) |
specific for human PDPN; the other clones: NZ-1.2( Sigma, Merck, MBL, Novus, Zenogen, Wako); NZ-1.3(Thermo), NC-08 (BioLegend) | IP, IHC, WB, FACS (Review; patent) |
NZ-1; KD
NZ-1.2 CTC; PIT |
done | BD (coming soon) |
| anti-human PDPN mAb (NZ-8; human IgG1) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP, IHC, WB, FACS | NZ-8 | done | |
| anti-human PDPN mAb (NZ-12; human IgG1) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP, IHC, WB, FACS | NZ-12 RIT |
done | |
| anti-human PDPN mAb (NZ-16; human IgG1) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP, IHC, WB, FACS | RIT | done | |
| anti-human PDPN mAb (NZ-27; human IgG1) |
specific for human PDPN; humanized mAb originated from NZ-1 | IP, IHC, WB, FACS |
NZ-27 CAR-T |
done | |
| anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa) | CasMab | IHC, WB, FACS | Cells2022 LpMab-2 patent |
done | |
| anti-hPDPN mAb (LpMab-3; mouse IgG1, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS | LpMab-3 epitope Structure |
done | MCP |
| anti-hPDPN mAb (LpMab-7 ;mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | LpMab-7 OS epitope |
done |
abcam MCP zenogen |
| anti-human PDPN mAb (chLpMab-7; human IgG1) | specific for human PDPN; mouse-human chimeric mAb originated from LpMab-7 | IHC, WB, FACS | chLpMab-7 | done | |
| anti-hPDPN mAb (LpMab-9; mouse IgG1, kappa) | specific for human PDPN; epitope: Thr25 | WB, FACS | LpMab-9 epitope |
done | MCP |
| anti-hPDPN mAb (LpMab-10; mouse IgG3, kappa) | specific for human PDPN; epitope: PLAG1 Thr34 | IHC, WB, FACS | LpMab-10 | done | |
| anti-hPDPN mAb (LpMab-12; mouse IgG1, kappa) | specific for human PDPN; epitope: PLAG3 Thr52 | IHC, WB, FACS | LpMab-12 | done |
CST
Merck Hycult MCP zenogen |
| anti-hPDPN mAb (LpMab-13; mouse IgG1, kappa) | specific for human PDPN; epitope: PLAG2-3 | IHC, WB, FACS | LpMab-13 | done | Merck Hycult |
| anti-hPDPN mAb (LpMab-16; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | patent 2018-123699 | done | |
| anti-hPDPN mAb (LpMab-17; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS press release |
LpMab-17 | done |
BD Merck Hycult |
| anti-hPDPN mAb (LpMab-19; mouse IgG2b, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS, ADCC/CDC | LpMab-19 | done | Merck |
| anti-hPDPN mAb (LpMab-21; mouse IgG2a, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS, ADCC/CDC press release |
Cells2022 LpMab-21 in vivo |
done |
Merck
BioLegend MCP |
| anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa) | CasMab | IHC, WB, FACS | LpMab-23 IHC patent |
done |
BD exbio zenogen |
| mouse podoplanin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti mouse PDPN mAb (PMab-1; rat IgG2a, kappa) |
specific for mouse PDPN --> anti-human PDPN |
IHC, WB, FACS | PMab-1 PMab-1_LEC epitope |
done | abcam; MBL; Nov; Mer; BioL; BD |
| anti-mouse PDPN mAb (mPMab-1; mouse IgG2a,kappa) | specific for mouse PDPN | IHC, WB, FACS |
mPMab-1 |
done | |
| anti-mouse PDPN mAb (PMab-1-mG2a-f; mouse IgG2a,kappa) | specific for mouse PDPN | IHC, WB, FACS | done | ||
| rat podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-rat PDPN mAb (PMab-2; mouse IgG1, kappa) |
specific for rat PDPN | IHC, WB, FACS | PMab-2 PMab-2_epitope |
done |
abcam Merck BioLegend |
| rabbit podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-rabbit PDPN mAb (PMab-32; mouse IgG1, kappa) |
specific for rabbit PDPN | IHC, WB, FACS | PMab-32 epitope |
||
| dog podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-dog PDPN mAb (PMab-38; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-38;
SCC melanoma epitope |
done |
zenogen Wako |
| anti-dog PDPN mAb (P38Bf; dog IgGB, kappa) |
core fucose-deficient type B of PMab-38 | IHC, WB, FACS |
P38Bf P38B_in vivo ADC |
done | |
| anti-dog PDPN mAb (PMab-48; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-48 epitope |
done | zenogen |
| bovine podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-bovPDPN mAb (PMab-44; mouse IgG1, kappa) | specific for bovine PDPN | IHC, WB, FACS | PMab-44;
epitope goat; sheep; alpaca |
done | zenogen |
| cat podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-cat PDPN mAb (PMab-52; mouse IgM, kappa) |
specific for cat PDPN | IHC, WB, FACS | PMab-52;
epitope IHC-1; IHC-2 tiger PDPN |
done | zenogen |
| tiger podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-tiger PDPN mAb (PMab-231; mouse IgG2a, kappa) |
specific for tiger PDPN used as a negative control of mouse IgG2a in vivo (250_in vivo) |
IHC, WB, FACS | PMab-231 epitope; lion 250_in vivo |
done | zenogen |
| horse podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-horse PDPN mAb (PMab-219; mouse IgG2a, kappa) |
specific for horse PDPN | WB, FACS, IHC | PMab-219 epitope |
done | zenogen |
| anti-horse PDPN mAb (PMab-202; mouse IgG1, kappa) |
specific for horse PDPN | WB, FACS | PMab-202 epitope |
done | zenogen |
| pig podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-pig PDPN mAb (PMab-213; mouse IgG2b, kappa) |
specific for pig PDPN | WB, FACS, IHC | PMab-213 epitope LEC |
done | zenogen |
| anti-pig PDPN mAb (PMab-210; mouse IgG1, kappa) |
specific for pig PDPN | WB, FACS, IHC | PMab-210 epitope |
done | zenogen |
| goat podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-goat PDPN mAb (PMab-235; mouse IgG1, kappa) | specific for goat PDPN | IHC, WB, FACS | PMab-235 epitope |
done | zenogen |
| alpaca podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-aPDPN mAb (PMab-225; mouse IgG2b, kappa) | specific for alpaca PDPN | IHC, WB, FACS |
PMab-225 epitope |
done | zenogen |
| Tas_devil podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-TasPDPN PDPN (PMab-233; mouse IgG1, kappa) | specific for Tasmanian devil PDPN | IHC, WB, FACS | PMab-233 epitope |
done | zenogen |
| bear podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-bear PDPN mAb (PMab-241; mouse IgG2b, kappa) |
specific for bear PDPN | IHC, WB, FACS | PMab-241 epitope |
||
| anti-bear PDPN mAb (PMab-247; mouse IgG1, kappa) |
specific for bear PDPN | IHC, WB, FACS | PMab-247 IHC epitope |
done | zenogen |
| whale podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-whale PDPN mAb (PMab-237; mouse IgG1, kappa) |
specific for whale PDPN | IHC, WB, FACS | PMab-237 IHC epitope |
done | zenogen |
| sheep podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-sheep PDPN mAb (PMab-256; mouse IgG1, kappa) |
specific for sheep PDPN | IHC, WB, FACS | PMab-256 epitope |
done | zenogen |
| anti-sheep PDPN mAb (PMab-253; mouse IgM, kappa) |
specific for sheept PDPN | IHC, WB, FACS | PMab-253 | done | |
| anti-sheep PDPN mAb (PMab-260; mouse IgM, kappa) |
specific for sheep PDPN | IHC, WB, FACS | PMab-260 | done | |
| sea lion podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-seaPDPN mAb (PMab-269; mouse IgG1, kappa) | specific for sea lion PDPN | IHC, WB, FACS | PMab-269 epitope Steller Sea Lion |
done | |
| elephant podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-elePDPN mAb (PMab-265; mouse IgM, kappa) | specific for elephant PDPN | FACS | PMab-265 | ||
| anti-elePDPN mAb (PMab-295; mouse IgG1, kappa) | specific for elephant PDPN | FACS, WB, IHC | PMab-295 epitope |
done |
Ab.antibody |
| ferret podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-ferret PDPN mAb (PMab-241; mouse IgG2b, kappa) |
anti-bear PDPN mAb crossreacts with ferret PDPN | IHC, WB, FACS | PMab-241 | ||
| anti-ferret PDPN mAb (PMab-292; mouse IgG1, kappa) |
specific for ferret PDPN | IHC, WB, FACS | PMab-292 epitope |
done |
Ab.antibody |
| anti-ferret PDPN mAb (PMab-293; mouse IgM, kappa) |
specific for ferret PDPN | FACS, WB | |||
| hamster podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-hamPDPN mAb (PMab-281; mouse IgG3, kappa) | specific for hamster PDPN | FACS, IHC | PMab-281
epitope |
done | |
| anti-hamPDPN mAb (281-mG2a-f; mouse IgG2a, kappa) | specific for hamster PDPN; IgG2a version of PMab-281; used as a negative control of mouse IgG2a in vivo (H2Mab-214; H2Mab-77) | FACS, IHC |
PMab-281
epitope |
done | |
| giraffe podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-girPDPN mAb (PMab-301; mouse IgG1, kappa) | specific for giraffe PDPN Kd: 1.3 x 10-8 M |
FACS, WB, IHC | PMab-301 | ||
| panda podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-panPDPN mAb (PMab-314; mouse IgG1, kappa) | specific for panda PDPN Kd: 1.3 x 10-8 M |
FACS, WB | PMab-314 | ||
| hippopotamus podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-hipPDPN mAb (PMab-***; mouse IgG) | specific for hippopotamus PDPN | ||||
| rhinoceros podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-rhiPDPN mAb (PMab-***; mouse IgG) | specific for rhinoceros PDPN |
intracellular proteins
| ATRX | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-ATRX mAb (AMab-6; mouse IgG1, kappa) |
specific for human ATRX | IHC, WB | AMab-6 AMab-6_epitope AMab-6_IHC |
done | abcam |
| DGK | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-DGKalpha mAb (DaMab-2; mouse IgG1, kappa) |
specifi for DGKalpha | ICC | DaMab-2 epitope |
done | |
| anti-DGKalpha mAb (Da2mG2a; mouse IgG2a, kappa) |
specifi for DGKalpha | ICC | done | ||
| anti-DGKalpha mAb (DaMab-8; mouse IgG1, kappa) |
specific for DGKalpha | IHC | DaMab-8 |
done | |
| anti-DGKalpha mAb (Da8mG2a; mouse IgG2a, kappa) |
specific for DGKalpha | ICC, IHC |
|
done | |
| anti-DGKgamma mAb (DgMab-6; mouse IgG1, kappa) |
specific for DGKgamma | ICC | DgMab-6 |
done | |
| anti-DGKalpha mAb (Dg6mG2a; mouse IgG2a, kappa) |
specifi for DGKgamma | ICC | done | ||
| anti-DGKzeta mAb (DzMab-1; rat IgG2b, kappa) |
specific for DGKzeta | ICC |
DzMab-1 epitope |
done | |
| anti-DGKzeta mAb (Dz1mG2a; mouse IgG2a, kappa) |
specific for DGKzeta | ICC | done | ||
| anti-DGKeta mAb (DhMab-1;mouse IgG2c, kappa) |
specific for DGKeta | IHC | DhMab-1 | done | |
| anti-DGKalpha mAb (Dh1mG2a; mouse IgG2a, kappa) |
specifi for DGKeata | ICC | done | ||
| anti-DGKeata mAb (DhMab-4; mouse IgG2b, kappa) |
specific for DGKeta | IHC |
DhMab-4 ICC |
done | |
| anti-DGKalpha mAb (Dh4mG2a; mouse IgG2a, kappa) |
specifi for DGKeata | ICC | done | ||
| anti-DGKdelta mAb (DdMab-1; mouse IgG2c, kappa) |
specific for DGKdeta | IHC | DdMab-1 | done | |
| anti-DGKalpha mAb (Dd1mG2a; mouse IgG2a, kappa) |
specifi for DGKdelta | ICC | done |
| IDH | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-IDH1-R132H mAb (HMab-1; mouse IgG1, kappa) | specific for IDH1-R132H | IHC, WB | HMab-1 | done |
Merck
MBL; IBL; Sigma |
| anti-IDH1-R132H mAb (HMab-2; mouse IgG1, kappa) | specific for IDH1-R132H | IHC, WB | HMab-2 | done | abcam |
| anti-IDH1-R132S mAb (SMab-1; mouse IgG1, kappa) | specific for IDH1-R132S | IHC, WB | SMab-1 | done |
abcam
IBL; MBL Merck_Sigma |
| anti-IDH1-R132G mAb (GMab-r1; rat IgG2a, kappa) | specific for IDH1-R132G | IHC, WB | GMab-r1 |
abcam MBL |
|
| anti-IDH2-R172K mAb (KMab-1; rat IgG2b, kappa) | specific for IDH2-R172K | IHC, WB | KMab-1 | abcam MBL |
|
| anti-IDH2-R172M mAb (MMab-1; rat IgG2b, kappa) | specific for IDH2-R172M | IHC, WB | MMab-1 |
abcam MBL |
|
| anti-IDH2-R172W mAb (WMab-1; rat IgG2b, kappa) | specific for IDH2-R172W | IHC, WB | WMab-1 |
abcam MBL |
|
| anti-IDH2-R172S mAb (SMab-2; mouse IgG1, kappa) | specific for IDH2-R172S | IHC, WB | SMab-2 | abcam | |
| anti-IDH1 mAb (RMab-3; mouse IgG1, kappa) | specific for IDH1 | IHC, WB | RMab-3 |
BD MBL |
|
| anti-IDH1 mAb (RcMab-1; rat IgG2a, kappa) | specific for IDH1 | IHC, WB | RcMab-1 |
abcam CST MBL |
|
| anti-IDH2 mAb (RMab-22; mouse IgG2b, kappa) | specific for IDH2 | IHC, WB | RMab-22 | MBL | |
| anti-IDH2 mAb (KrMab-3; mouse IgG2b, kappa) | specific for IDH2 | IHC, WB | KrMab-3 | CST BioLegend MBL |
|
| anti-mIDH1/2 mAb (MsMab-1; mouse IgG1, kappa) | specific for mutated IDH1/2 | IHC, WB (ref) |
TJEM Brain Tumor Pathol Cancer Med |
done | abcam Merck |
| anti-mIDH1/2 mAb (MsMab-2; rat IgG2a, kappa) | specific for mutated IDH1/2 | IHC, WB | MsMab-2 | done | MBL |
| TERT | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mTERT mAb (TmMab-1; rat IgG1, kappa) |
specific for mTERT | ELISA, WB | done | ||
| anti-mTERT mAb (TmMab-2; rat IgG2a, kappa) |
specific for mTERT | ELISA | done | ||
| anti-mTERT mAb (TmMab-3; rat IgG1, kappa) |
specific for mTERT | ELISA, WB | done | ||
| anti-mTERT mAb (TmMab-4; rat IgG1, kappa) |
specific for mTERT | ELISA | done | ||
| anti-hTERT mAb (TpMab-1; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA |
TpMab-1 (press release) |
done | |
| anti-hTERT mAb (TpMab-2; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA | done | ||
| anti-hTERT mAb (TpMab-3; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA |
TpMab-3 (press release) accept |
done | Merck |
| anti-hTERT mAb (TpMab-35; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | ICC, WB, ELISA | accept | ||
| anti-hTERT mAb (TwMab-1; mouse IgG1, kappa) |
specific for hTERT | IHC, WB, ELISA | TwMab-1 | done | Merck |
| anti-hTERT mAb (TMab-6; mouse IgM, kappa) |
specific for hTERT | IHC |
TMab-6 TMab-6_epitope |
done |
Monoclonal antibodies for SARS-CoV-2
| SARS-CoV-2 (S1 RBD) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-1; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 319-338 aa RBD: Receptor binding domain |
ELISA,WB, IHC | done | ||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-2; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC, neutralization | |||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-3; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 469-478 aa |
ELISA,WB, IHC, neutralization | |||
| anti SARS-CoV-2 S1-RBD mAb (CvMab-6; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC, neutralization | CvMab-6 | done | |
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-7; mouse IgM, kappa) |
specific for SARS-CoV-2 S1-RBD epitope:459-478 aa |
ELISA, WB, IHC, neutralization | done | ||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-13; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC | done | ||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-17; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, neutralization, IHC | |||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-18; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, neutralization, IHC | |||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-24; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC, neutralization | |||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-25; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, IHC, WB |
| SARS-CoV-2 (S1 N terminus) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 mAb (CvMab-32; mouse IgG2b, kappa) |
specific for SARS-CoV-2 S1N terminus | ELISA, IHC, WB |
| SARS-CoV-2 (S2) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 mAb (CvMab-36; mouse IgG1, kappa) |
specific for SARS-CoV-2 S2 | ELISA, WB | |||
| anti-SARS-CoV-2 mAb (CvMab-62; mouse IgG1, kappa) |
specific for SARS-CoV-2 S2 | ELISA | CvMab-62 | done | |
| anti-SARS-CoV-2 mAb (humCvMab-62; human IgG1, kappa) |
specific for SARS-CoV-2 S2 | ELISA | done |
| SARS-CoV-2 (bi-specific) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 mAb (CvMab-bis1) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-6-H_CvM62scFv |
CvMab-bis1 | done | ||
| anti-SARS-CoV-2 mAb (CvMab-bis2) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-6-L_CvM62scFv |
CvMab-bis2 | done | ||
| anti-SARS-CoV-2 mAb (CvMab-bis3) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-62-H_CvM6scFv |
CvMab-bis3 | done | ||
| anti-SARS-CoV-2 mAb (CvMab-bis4) |
specific for SARS-CoV-2 S1+S2
bispecific mAb CvMab-62-L_CvM6scFv |
CvMab-bis4 | done | ||
| CvMab-62-H_Bebtelovimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | CvMab-62-H_Bebtelovimab | done | ||
| humCvMab-62-H_Bebtelovimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | done | |||
| CvMab-62-H_Cilgavimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | done |
| SARS-CoV-2 (humanized) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| Bebtelovimab (human IgG1, lambda) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) |
Neutralization; weak activity for all variants | done | ||
| Cilgavimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) Cilgavimab plus tixagevimab (EVUSHELD) |
Neutralization; weak activity for BA.2; resistant for BA.4/5 | done | ||
| Casirivimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) Casirivimab plus imdevimab (Ronapreve) |
Neutralization; weak activity for Omicron | done | ||
| Bamlanivimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) |
Neutralization; no activity for Omicron | done | ||
| Bebtelovimab-scFv (scFv-Fc of human IgG1) |
specific for SARS-CoV-2 S1 | done | |||
| Cilgavimab-scFv (scFv-Fc of human IgG1) |
specific for SARS-CoV-2 S1 | done |
| RdRP | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-RdRP mAb (RdMab-2; mouse IgG2a, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV | ELISA, WB, IP, ICC | RdMab-2 | done | |
| anti-RdRP mAb (RdMab-13; mouse IgM, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB | RdMab-13 | ||
| anti-RdRP mAb (RdMab-15; mouse IgG1, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP ; Immunogen: RHTFSNYQHEETIYNLLKDC |
ELISA, WB | RdMab-15 | ||
| anti-RdRP mAb (RdMab-16; mouse IgG1, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP ; Immunogen: RHTFSNYQHEETIYNLLKDC |
ELISA, WB | RdMab-16 | ||
| anti-RdRP mAb (RdMab-20; mouse IgG2b, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB | RdMab-20 |
anti-dog protein monoclonal antibodies
| dog PDPN | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-dog PDPN mAb (PMab-38; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-38;
SCC melanoma epitope |
done |
zenogen Wako |
| anti-dog PDPN mAb (P38Bf; dog IgGB, kappa) |
core fucose-deficient type B of PMab-38 | IHC, WB, FACS |
P38Bf P38B_in vivo ADC |
done | |
| anti-dog PDPN mAb (PMab-48; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-48 epitope |
done | zenogen |
| dog EGFR | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (134-mG2a-f; mouse IgG2a, kappa) |
core fucose-deficient mouse IgG2a version of EMab-134; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | CHO/dEGFR Osteosarcoma Fibroblastic Mammary |
done | |
| anti-EGFR mAb (E134Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of EMab-134; specific for EGFR | FACS, WB, IHC, ADCC, CDC, antitumor activities | Mammary Fibro & Osteo |
done | |
| dog HER2 | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H77Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of H2Mab-77 | FACS, WB, IHC, ADCC/CDC, antitumor activities | H77Bf OS fibro |
done | |
| anti-HER2 mAb (H2Mab-41; mouse IgG2b, kappa) |
specific for HER2; crossreacts with dog HER2; domain-IV | FACS, antitumor activities | H2Mab-41
dogHER2 |
done | |
| EGFR-HER2 (bispecific) | Character | Application | Ref | Gene cloning | Company |
| anti-dog EGFR-dog HER2 mAb (E134B-H77scFv-f) |
bispecific mAb for EGFR and HER2 | FACS, WB, IHC, ADCC, CDC, antitumor activities | E134B-H77scFv-f | done | |
| dog PD-L1 | Character | Application | Ref | Gene cloning | Company |
| anti-dog PD-L1 mAb (L1Mab-347; mouse IgG1, kappa) |
specific for dog PD-L1 | FACS, IHC | done | ||
| anti-dog PD-L1 mAb (L1Mab-348; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-349; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-350; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-351; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-352; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-352 | done | |
| anti-dog PD-L1 mAb (L1Mab-353; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-354; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-354 | done | |
| anti-dog PD-L1 mAb (L1Mab-355; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-356; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA |
CasMab
| PDPN | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa) | CasMab; patent | IHC, WB, FACS | PDPN_review LpMab-2 |
done | zenogen |
| anti-human PDPN mAb(chLpMab-2; human IgG1, kappa) |
CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-2 | IP, IHC, WB, FACS | chLpMab-2 | done | zenogen |
| anti-hPDPN mAb (LpMab-2-scFv; scFv) |
CasMab for human PDPN; scFv originated from LpMab-2 |
CART | CART | done | |
| anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa) | CasMab | IHC, WB, FACS | LpMab-23 IHC patent |
done |
BD exbio zenogen |
| anti-human PDPN mAb (chLpMab-23; human IgG1) | CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-23 | IHC, WB, FACS | chLpMab-23 | done | zenogen |
| anti-human PDPN mAb (humLpMab-23-f; human IgG1) | CasMab for human PDPN; humanized mAb originated from LpMab-23 | IHC, WB, FACS | humLpMab-23-f | done | zenogen |
| anti-hPDPN mAb (humLpMab-23-scFv) | CasMab for human PDPN; scFv originated from LpMab-23 |
CART | in preparation | done | |
| anti-hPDPN mAb (PMab-117; rat IgM, kappa) | CasMab | FACS | Cells2022 patent |
done | zenogen |
| Podocalyxin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PODXL mAb (PcMab-6; mouse IgG1, kappa) |
anti-PODXL CasMab | FACS | PcMab-6 patent |
done | zenogen |
| anti-PODXL mAb (PcMab-6-mG2a-f; mouse IgG2a) |
anti-PODXL CasMab; IgG2a version of PcMab-6 | FACS, ADCC/CDC | PcMab-6-mG2a-f | done | zenogen |
| anti-PODXL mAb (PcMab-6-hG1-f; human IgG1) |
anti-PODXL CasMab; human IgG1 version of PcMab-6 | FACS, ADCC/CDC | done | zenogen | |
| anti-PODXL mAb (humPcMab-6-f; human IgG1) |
CasMab for PODXL; humanized mAb originated from PcMab-6 | FACS | humPcMab-6-f | done | zenogen |
| anti-hPDPN mAb (humPcMab-6-scFv; scFv) | CasMab; scFv originated from PcMab-6 | CART | in preparation | done | |
| anti-PODXL mAb (PcMab-60; mouse IgM, kappa) |
anti-PODXL CasMab | FACS | PcMab-60 epitope patent |
done | zenogen |
| anti-PODXL mAb (60-mG2a; mouse IgG2a, kappa) |
anti-PODXL CasMab; IgG2a version of PcMab-60 | FACS, ADCC/CDC | 60-mG2a | done | zenogen |
| anti-PODXL mAb (60-mG2a-f; mouse IgG2a, kappa) |
anti-PODXL CasMab, core fucose-deficient IgG2a version of PcMab-60 | FACS, ADCC/CDC, antitumor activities | 60-mG2a-f | done | zenogen |
| anti-PODXL mAb (PcMab-60-hG1-f; human IgG1) |
anti-PODXL CasMab; human IgG1 version of PcMab-60 | FACS, ADCC/CDC | done | zenogen | |
| anti-PODXL mAb (humPcMab-60; human IgG1) |
anti-PODXL CasMab; humanized PcMab-60 | FACS, ADCC/CDC | done | zenogen | |
| anti-hPDPN mAb (humPcMab-60-scFv; scFv) | CasMab; scFv originated from PcMab-60 | CART | done |
| CD44s | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44s mAb (C44Mab-1012; mouse IgM, kappa) |
Mab1 for CD44s (exon-6) cossreact with mouse CD44 |
FACS | done | ||
| anti-CD44s mAb (C44Mab-1012-mG1; mouse IgG1) |
Mab1 for CD44s (exon-6) | FACS | done | ||
| anti-CD44s mAb (C44Mab-1012-hG1; human IgG1) |
Mab1 for CD44s (exon-6) | FACS | done | ||
| anti-CD44s mAb (C44Mab-1075; mouse IgG2a, kappa) |
Mab2 for CD44s (exon-6) | FACS | done | ||
| anti-CD44s mAb (C44Mab-1095; mouse IgG1, kappa) |
Mab3 for CD44s (exon-6) | FACS | done |
| CD44v3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44v3 mAb (C44Mab-1080; mouse IgG1, kappa) |
Mab6 for CD44v3 | FACS, WB, IHC | done | ||
| anti-CD44v3 mAb (C44Mab-1006; mouse IgG1, kappa) |
Mab11 for CD44v3 | FACS, WB, IHC | done | ||
| CD44v5 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v5 mAb (C44Mab-1088; mouse IgG1, kappa) |
Mab8 for CD44v5 | FACS, WB, IHC | done | ||
| anti-CD44v5 mAb (C44Mab-1003; mouse IgG1, kappa) |
Mab12 for CD44v5 | FACS, WB, IHC | done | ||
| CD44v6 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v6 mAb (C44Mab-1081; mouse IgG1, kappa) |
Mab7 for CD44v6 | FACS, WB, IHC | done | ||
| anti-CD44v6 mAb (C44Mab-1089; mouse IgM, kappa) |
Mab9 for CD44v6 | FACS, WB, IHC | done | ||
| anti-CD44v6 mAb (C44Mab-1009; mouse IgG1, kappa) |
Mab13 for CD44v6 | FACS, WB, IHC | done | ||
| anti-CD44v6 mAb (C44Mab-1074; mouse IgM, kappa) |
Mab14 for CD44v6 | FACS, WB, IHC | done | ||
| anti-CD44v6 mAb (C44Mab-1079; mouse IgG1, kappa) |
Mab15 for CD44v6 | FACS, WB, IHC | done | ||
| anti-CD44v6 mAb (C44Mab-1092; mouse IgG3, kappa) |
Mab16 for CD44v6 | FACS, WB, IHC | done | ||
| CD44v7 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v7 mAb (C44Mab-1030; mouse IgM, kappa) |
Mab4 for CD44v7 | FACS, WB, IHC | done | ||
| anti-CD44v7 mAb (C44Mab-1048; mouse IgG1, kappa) |
Mab5 for CD44v7 | FACS, WB, IHC | done | ||
| anti-CD44v7 mAb (C44Mab-1034; mouse IgG1, kappa) |
Mab10 for CD44v7 | FACS, WB, IHC | done |
| EpCAM | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EpCAM mAb (EpMab-1123; mouse IgM, kappa) |
Mab1 for EpCAM | FACS | x | ||
| anti-EpCAM mAb (EpMab-1138; mouse IgM, kappa) |
Mab2 for EpCAM | FACS | x | ||
| anti-EpCAM mAb (EpMab-1147; mouse IgG1, kappa) |
Mab3 for EpCAM | FACS | done | ||
| anti-EpCAM mAb (EpMab-1007; mouse IgG1, kappa) |
Mab4 for EpCAM | FACS | done | ||
| anti-EpCAM mAb (EpMab-1013; mouse IgG1, kappa) |
Mab5 for EpCAM | FACS | done | ||
| anti-EpCAM mAb (EpMab-1022; mouse IgG1, kappa) |
Mab6 for EpCAM | FACS | done | ||
| anti-EpCAM mAb (EpMab-1069; mouse IgG1, kappa) |
Mab7 for EpCAM | FACS | done |
| TROP2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-TROP2 mAb (TrMab-1100; mouse IgG1, kappa) |
Mab1 for human TROP2 | FACS | done | ||
| anti-TROP2 mAb (TrMab-1148; mouse IgG1, kappa) |
Mab3 for human TROP2 | FACS | done | ||
| anti-TROP2 mAb (TrMab-1156; mouse IgG2b, kappa) |
Mab4 for human TROP2 | FACS | done |
| EGFR | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti EGFR mAb (EMab-1048; mouse IgM,kappa) |
Mab1 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1059; mouse IgG1,kappa) |
Mab2 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1073; mouse IgG1,kappa) |
Mab3 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1092; mouse IgG1,kappa) |
Mab4 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1094; mouse IgG1,kappa) |
Mab5 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1096; mouse IgM,kappa) |
Mab6 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1102; mouse IgG1,kappa) |
Mab7 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1106; mouse IgG1,kappa) |
Mab8 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1107; mouse IgG1,kappa) |
Mab9 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1111; mouse IgG1,kappa) |
Mab10 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1119; mouse IgG1,kappa) |
Mab11 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1122; mouse IgG1,kappa) |
Mab12 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1141; mouse IgG1,kappa) |
Mab13 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1146; mouse IgG1,kappa) |
Mab14 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1152; mouse IgG1,kappa) |
Mab15 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1153; mouse IgG1,kappa) |
Mab16 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1190; mouse IgG1,kappa) |
Mab17 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1196; mouse IgG1,kappa) |
Mab18 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1225; mouse IgG1,kappa) |
Mab19 for EGFR | FACS | done | ONO | |
| anti EGFR mAb (EMab-1243; mouse IgM,kappa) |
Mab20 for EGFR | FACS | done | ONO |
| HER2 (CD340) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb (H2Mab-214; mouse IgG1,kappa) |
Mab-1; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | H2Mab-214 | done | ONO |
| anti-HER2 mAb (H2Mab-214-mG2af; mouse IgG2a,kappa) |
Mab-1; specific for HER2; domain-IV | FACS, WB, IHC | 214-mG2a-f | done | ONO |
| anti-HER2 mAb (H2Mab-214-hG1; human IgG1,kappa) |
Mab-1; specific for HER2; domain-IV | FACS, WB, IHC | done | ONO | |
| anti-HER2 mAb (H2Mab-250; mouse IgG1,kappa) |
Mab-2; specific for HER2; domain-IV | FACS, WB, IHC | H2Mab-250 250_in vivo |
done | ONO |
| anti-HER2 mAb (H2Mab-250-mG2af; mouse IgG2a,kappa) |
Mab-2; specific for HER2; domain-IV | FACS, WB, IHC | H2Mab-250 250_in vivo |
done | ONO |
| anti-HER2 mAb (H2Mab-250-hG1-f; human IgG1,kappa) |
Mab-2; specific for HER2; domain-IV | FACS, WB, IHC | 250_in vivo | done | ONO |
| anti-HER2 mAb (H2Mab-250-scFv) |
Mab-2; specific for HER2; domain-IV |
CART | FT825 | done | ONO, Fate |
| anti-HER2 mAb (H2Mab-1279; mouse IgG3,kappa) |
Mab-3; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1280; mouse IgG1,kappa) |
Mab-4; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1281; mouse IgG1,kappa) |
Mab-5; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1282; mouse IgG2a,kappa) |
Mab-6; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1283; mouse IgG1,kappa) |
Mab-7; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1284; mouse IgG1,kappa) |
Mab-8; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1285; mouse IgG3,kappa) |
Mab-9; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1286; mouse IgG1,kappa) |
Mab-10; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1287; mouse IgG1,kappa) |
Mab-11; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1288; mouse IgG1,kappa) |
Mab-12; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1289; mouse IgG1,kappa) |
Mab-13; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1290; mouse IgG1,kappa) |
Mab-14; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1291; mouse IgG3,kappa) |
Mab-15; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1292; mouse IgG3,kappa) |
Mab-16; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1293; mouse IgG3,kappa) |
Mab-17; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1294; mouse IgG1,kappa) |
Mab-18; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1295; mouse IgG1,kappa) |
Mab-19; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1296; mouse IgG1,kappa) |
Mab-20; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1297; mouse IgG2a,kappa) |
Mab-21; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1298; mouse IgG1,kappa) |
Mab-22; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1299; mouse IgG1,kappa) |
Mab-23; specific for HER2; domain-IV | FACS, WB, IHC | PCT/JP2021/043538 | done | ONO |
| anti-HER2 mAb (H2Mab-1301; rat IgG2a, lambda) |
Mab30; specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | ||
| anti-HER2 mAb (H2Mab-1301-hG1 ;human IgG1,kappa) |
specific for mouse HER2;
cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | ||
| anti-HER2 mAb (H2Mab-1316; rat IgG2a, kappa) |
Mab-31; specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | ||
| anti-HER2 mAb (H2Mab-1316-hG1 ;human IgG1,kappa) |
specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | ||
| anti-HER2 mAb (H2Mab-1319; rat IgG2a, kappa) |
Mab-32; specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | ||
| anti-HER2 mAb (H2Mab-1319-hG1 ;human IgG1,kappa) |
specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | ||
| anti-HER2 mAb (H2Mab-1180; mouse IgG1, kappa) |
Mab-33; specific for human HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
| anti-HER2 mAb (H2Mab-1245; mouse IgG1,kappa) |
Mab-34; specific for human HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
| anti-HER2 mAb (H2Mab-1268; mouse IgG1,kappa) |
Mab-35; specific for HER2 or endogenous dog HER2 | FACS | done | ||
| anti-HER2 mAb (H2Mab-1190; mouse IgG1,kappa) |
Mab-36; specific for HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
| anti-HER2 mAb (H2Mab-1262; mouse IgG1,kappa) |
Mab-37; specific for HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
| anti-HER2 mAb (H2Mab-1278; mouse IgG1,kappa) |
Mab-38; specific for HER2 or endogenous dog HER2 | FACS | done |
| HER3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti HER3 mAb (H3Mab-1059; mouse IgG1,kappa) |
Mab1 for HER3 | FACS | done | ||
| anti HER3 mAb (H3Mab-1170; mouse IgG1,kappa) |
Mab2 for HER3 | FACS | done |